Data for: A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study
2019
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI